Centrient Pharmaceuticals achieves milestone in antibiotics clean production

KUALA LUMPUR, May 19 (Bernama) -- Centrient Pharmaceuticals has announced 100 per cent compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral antibiotics product range.

This standard covers both Centrient’s sites and its suppliers’ sites, an achievement positioning the company as a frontrunner in the industry with the delivery of responsibly-produced antibiotics, which minimise the possible contribution to antimicrobial resistance.

According to a statement, the PNEC discharge target is the concentration of an antibiotic in water at which there is unlikely to be a risk of adverse environmental effects or of antimicrobial resistance (AMR) developing.

These scientific, risk-based targets were developed by the AMR Industry Alliance and cover around 120 active pharmaceutical ingredients (APIs) used in antibiotic manufacturing. Each individual antibiotic has a corresponding PNEC value, published in the AMR Industry Alliance table of Recommended PNECs for Risk Assessments (updated periodically).

High concentrations of antibiotic residues in factory wastewater can create hotspots of resistant bacteria which may lead to AMR. While manufacturing is just one of the contributors to the emergence of AMR in the environment, its impact cannot be overlooked. AMR is a major threat to global public health as well as to the healthcare industry.

Many standard medical procedures such as organ transplants, chemotherapy, and surgeries such as caesarean sections become much more dangerous without effective antibiotics to prevent and treat infections.

“At Centrient Pharmaceuticals, our commitment to Sustainability is in our DNA – we ensure that the way in which we produce pharmaceuticals has the lowest environmental impact and does not contribute to AMR.

“We are proud of our PureActives® enzymatic low-carbon technology, ISO 14001 certification of all our sites, and Board positions at the Pharmaceutical Supply Chain Initiative and AMR Industry Alliance,“ said Rex Clements, CEO at Centrient Pharmaceuticals.

-- BERNAMA